At SUFU 2026, 24-month data from the TITAN 2 trial showed that the Altaviva ITNM system provided sustained reductions in urgency urinary incontinence episodes, durable quality-of-life improvements, and a favorable safety profile through 24 months.
Joshua Fitch
Advertisement
Articles by Joshua Fitch
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Study suggests potential diuretic effect with nadofaragene firadenovec
5